Lepu Biopharma Co (HKSE:02157) Debt-to-Equity : 0.85 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co Debt-to-Equity?

Lepu Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$566.4 Mil. Lepu Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$267.8 Mil. Lepu Biopharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$984.8 Mil. Lepu Biopharma Co's debt to equity for the quarter that ended in Jun. 2024 was 0.85.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lepu Biopharma Co's Debt-to-Equity or its related term are showing as below:

HKSE:02157' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.64 Med: 0.58 Max: 1.02
Current: 1.2

During the past 6 years, the highest Debt-to-Equity Ratio of Lepu Biopharma Co was 1.02. The lowest was -1.64. And the median was 0.58.

HKSE:02157's Debt-to-Equity is ranked worse than
89.58% of 1017 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02157: 1.20

Lepu Biopharma Co Debt-to-Equity Historical Data

The historical data trend for Lepu Biopharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co Debt-to-Equity Chart

Lepu Biopharma Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.40

0.77

0.83

1.20

Lepu Biopharma Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial					0.77	1.02	0.83	0.85	1.20

Competitive Comparison of Lepu Biopharma Co's Debt-to-Equity

For the Biotechnology subindustry, Lepu Biopharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lepu Biopharma Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lepu Biopharma Co's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Lepu Biopharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lepu Biopharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(506.024	+	310.834)	/	981.016
	=	0.83

Lepu Biopharma Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(566.351	+	267.845)	/	984.769
	=	0.85

Lepu Biopharma Co (HKSE:02157) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lepu Biopharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lepu Biopharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lepu Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201612

Website

https://www.lepubiopharma.com

Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.

Executives

Pu Zhongjie	2201 Interest of corporation controlled by you
Hu Chaohong	2201 Interest of corporation controlled by you
Pu Jue	2201 Interest of corporation controlled by you
Hao Chunmei	2202 Interest of your spouse
Su Rongyu	2101 Beneficial owner
Miracogen Inc.	2201 Interest of corporation controlled by you
Miracogen Limited	2101 Beneficial owner
Cereblue Limited	2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si	2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si	2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si	2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines